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ABSTRACT
Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous unit. Recent studies
have shown an increasing number of cases of acne in adult women. These cases are predominantly
normoandrogenic and present some clinical differences compared to adolescent acne. Local
glandular metabolism turns some weak hormonal precursors into more active substances that
increase the production of sebum, leaving these areas more prone to an increasing the colonization
by Propionibacterium acnes (P. acnes). Our objective was to evaluate the usefulness of an
androgenic metabolite as an adult female acne biomarker. The study population consisted of 38
adult women with acne without any features of hyperandrogenism and a control group. They were
recruited from the clinic of Dermatology Hospital Division of S~ao Paulo, Federal University of S~ao
Paulo from January 2012 to September 2014. After the first hormonal dosages, patients with acne
were randomized into two different groups: one receiving a combined oral contraceptive (COC)
containing 0,02 mg of ethinylestradiol and 3 mg drospirenone in a regimen of 24 days of
medication, and the other group was treated with a topical gel containing 15% azelaic acid (AA),
twice daily, both for six months. With the end of treatment new dosages were performed.
Regarding the hormones, total and free testosterone and dehydroepiandrosterone sultate were
quantified. In addition, the detection and quantification of androsterone glucuronate (ADT-G), an
androgenic metabolite, has been developed. Only ADT-G was sensitive in detecting differences
between the control and acne groups, and presented reduction of their values with systemic
treatment. Therefore, only ADT-G was able to analyze the peripheral hyperandrogenism in cases of
adult female acne.
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Introduction
Researchers analyzing epidemiological data of adult
acne showed prevalence increased in women
beyond 26 years old, indicating a statistically sig-
nificant difference when compared to men. The
prevalence in women ranges from 14–20% com-
pared to 3–5% for men.1-5 Furthermore, lesions in
adult women are more intense. Clinically, they
have moderate acne involving the lower face and
lateral neck. In contrast, the typical presentation in
adolescents involves the frontal area, nose, and
malar area.6 Not all adults have this pattern of dis-
tribution, and the presence of a large number of
comedones was reported in smokers.7,8 Usually,
these patients have no hormonal abnormalities.
They have a prolonged evolution with chronic skin
inflammation.9
Sebaceous gland, among other peripheral tissues, is
able to transform weak hormone precursors into potent
androgens [testosterone (T) and dihydrotestosterone
(DHT)]. Its cytoplasm contains all the six enzymes
needed for androgenic amplification. This function is
known as peripheral conversion and in the end stimu-
lates increased sebum production.10,11 A minimal
amount of the potent intracellular androgenic products
reach the circulation, therefore the major action is
restricted to the sebocyte. Increased sebaceous produc-
tion favors colonization by P. acnes.12
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Androgens need to be metabolized in water-soluble
substances to be excreted. Thus, all androgens, regard-
less of the location of their production, are eliminated
by sulfation and glucuronidation processes.13 Andros-
terone glucuronide (ADT-G) accounts for more than
70% of these metabolites.14 Although, most of the
time, its dosage is performed by radioimmunoassay,
this technique presents low specificity and sensitivity
when compared to new laboratory analytical methods
such as liquid chromatography associated with mass
spectrometry.15-17
Another androgenic metabolite, known as 3 alpha-
androstanediol glucuronide (3 alpha diol-G) of molec-
ular weight very close to ADT-G; 468,58 g/mol and
466,56 g/mol respectively; was studied in acne cases
but has proved useful as a biomarker only when
hirsutism is present in association.18-19
Objective
The objective of this study was to develop a precision
laboratory analysis to verify if the ADT-G would serve
as a biomarker of peripheral hyperandrogenism in
cases of patients with adult female acne.
Methods
Women between 26 and 44 years old were the study
population. The acne group had diagnosis of mild to
moderate acne, affecting the face and, healthy women
with the same age range composed the control group.
The Research Ethics Committee – Federal Univer-
sity of S~ao Paulo, approved the project / Hospital
S~ao Paulo, on November 4, 2011, under no. 1622/11
and was enrolled in Clinicaltrials.gov – Identifier:
NCT01850095.
Patients with signs and symptoms of clinical hyper-
androgenism such as hirsutism, androgenetic alopecia
and irregular menses, were excluded.
Transvaginal ultrasonography and free / total tes-
tosterone (FT/TT) and dehydroespandrosterone sul-
fate (S-DHEA) dosages were performed in all women.
Only the subjects with the exams within the reference
range remained in the study.
The acne group (38 women) was randomized into
two groups (software: random.org) in order to be
treated with two distinct medications. One group was
treated with azelaic acid (AA) 15% in gel, bid, for
6 months and the other group with combined oral
contraceptive (COC) containing ethinylestradiol
0.02 mg and drospirenone 3 mg at the same time. Ten
healthy women were included in the control group.
New blood samples were collected before and after the
treatment. Inflammatory lesions count and photographic
records were made to analyze the treatment evolution.
The ADT-G dosage was performed with a new “in-
house” methodology using solid phase extraction and
quantification by liquid chromatography associated
with sequential mass spectrometry (LC-MS/MS).
Detection and quantification of ADT-G
The ADT-G analysis was performed by LC-MS/MS,
operating in the electrospray-negative mode. On the
analysis’s day, calibrations with standards, ranging
from 1 to 100 ng / ml were prepared.
Extraction of samples
Briefly, 200 mL of each plasma sample was mixed
with 200 mL of acetonitrile (ACN) and 20 mL of a
solution containing the deuterated internal standard
(ADT-G-d4). This mixture was stirred in individual
tubes for 2 minutes and then centrifuged at
14000 rpm for 10 minutes.
The samples were transferred to the solid phase
extraction columns (SAX column – strong anion
exchange) after being activated with ACN and equili-
brated with water. After application of the samples,
the columns were washed with 1 mL of water. The
analytes of interest were eluted with 1 mL of a solution
containing 95% ACN and 1% formic acid. The eluates
were evaporated in vacuum for 2 hours. The dried res-
idue was reconstituted in 50 mL solution of 50/50 mix
methanol/water.
Analysis by liquid chromatography tandem-mass
spectrometry (LC-MS/MS)
The derivative was analyzed by LC-MS/MS operating
in the negative electrospray mode using a system com-
posed of an Acquity binary pump and XEVO TQS
(Waters) mass spectrometer with CTC 2777 injector.
It was used a column Gemini NX 3 mm C18 150 £
2 mm. Total running time was 2 minutes. ADT-G and
ADT-G-d4 were detected by monitoring selected
reactions (MRM) using two transitions for each
analyte. Data were processed and quantified by
TargetLynx software (Waters). The method was vali-
dated according to the CLSI guidelines and
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parameters such as linearity, precision, limit of quanti-
fication, and recovery were evaluated.
Statistical analysis
Qualitative variables were described as number
and percentage, and quantitative variables were
described by means of central tendency (mean and
median) and variability measures (standard deviation,
standard error and inter-quartile interval).
A model of analysis of variance (ANOVA) with
repeated measures was used to compare the number
of inflammatory lesions counted by the investigator
before and after the treatments (COC and AA).
For the comparison between the two treatments
regarding the general appearance of the skin per-
formed by the independent examiners in the photo-
graphic evaluation, the Fischer exact test was used.
All statistical analyzes were performed with SPSS
software version 16.0 (SPSS Inc., Illinois, USA). All
tests were two-tailed and p value <0.05 was consid-
ered statistically significant.
Results
Table 1 shows the initial population characteristics.
The statistical analysis proved the homogeneity of the
studied groups.
Clinical evolution
The clinical evolution, analyzed by the two inde-
pendent dermatologists, was considered efficient
with both treatments. However, for the examiner 1
there was no significant difference between the
groups (Fisher’s exact test p D 0.180) and for the
examiner 2, the group treated with COC presented
a superior improvement with statistical significance
in relation to the group treated with azelaic acid
(p D 0.002). A significant decrease in mean num-
ber of lesions after treatments was observed in
both groups (p < 0.001).
Hormones and ADT-G
Before the treatment
Statistical analyses proved that the subgroups were
homogenous for ADT-G values, before the treatments
(p D 0.559 – Student’s t-Test). Figure 1 shows a signif-
icant difference between the groups (p D 0.013), with
a mean value of 10.4 § 4.0 ng / ml (95%
CI – [2,3]), higher in acne group. No difference was
found with the other hormones analyzed.
Treatment influence
According to the Fig. 2, the ADT-G levels at the AA
group did not present significant variation from before
and after the treatment. However, the COC group pre-
sented a significant decrease in the mean ADT-G from
before to after the treatment (p D 0.029).
According to the Fig. 3, at the AA subgroup, the FT
mean levels did not change with the treatment. On the
other hand, in the COC group, a significant difference
was observed (p < 0.001).
Table 1. Clinical and demographic data according to the treat-
ment subgroups.
TREATMENT
COC(n D 20) AA(nD 18) p-valor
Agea (years) 33,7 § 5,5 33,1 § 5,3 0,695#
Smoking 1 (5,0%) 2 (11,8%) 0,584##
“U type” lesion distribution 14 (70,0%) 13 (72,2%) >0,999##
Onset of acne 0,516&
adolescence 9 (45,0%) 10 (55,6%)
adult 11 (55,0%) 8 (44,4%)
Intensity 0,132###
none — —
comedones and rare papules 1 (5,0%) 1 (5,6%)
predominance of papules
and pustules
18 (90,0%) 12 (66,7)
nodules 1 (5,0%) 5 (27,8%)
aamean§ standanrd deviation.
#Student T test /.
##Fisher’s exact test /.
###generalization of Fishers’s exact test.
&chi-square.
Figure 1. Error bar graphs representing mean § standard devia-
tion values obtained in ADT-G levels in acne and control groups,
before treatment.
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Total testosterone and S-DHEA mean levels
showed no significant variation with treatment.
Discussion
In general, almost all patients with acne present
increased sebaceous secretion. Some studies have
demonstrated an increase in 5a-reductase activity
and higher androgen receptors expression in
sebocytes.14,20
However, even with normal androgenic levels, seba-
ceous glands may be hyperactive. Sebocytes have all
the necessary enzymes for conversion weak hormonal
precursors in more potent ones, which act on intracel-
lular receptors.21
In this study, we sought to indirectly verify the
androgenic peripheral activation, performed by
many tissues including the skin, by the dosage of
the most frequent androgenic metabolite, ADT-G.
The mean values of the laboratory dosages were
used to verify the existence of significant differen-
ces between the studied groups.
No differences were observed regarding the levels
of TT, FT and DHEA-S among the two groups
before the treatment. This is consistent with most
previous studies that classify these patients as
“normoandrogenic”.22
However, we believe the best term would be “nor-
moadrogenemic,” which means: with no plasma
androgen elevation.
Thus, TT / FT and DHEA-S were not useful as
androgenic markers in these patients with isolated
acne. Previous studies have confirmed that TT and FT
are not capable of analyzing the total androgen activity
and that they would be helpful only in monitoring
patients with hirsutism associated or not with acne.23
The ADT-G levels, obtained by a high specificity
and sensitivity analytical chemistry technique (liquid
chromatography tandem-mass spectrometry) showed
a significant increase in mean values, 10.4 § 4 ng / ml,
in the comparison between the acne and the control,
allowing to conclude that this biomarker was able to
differentiate the groups. The levels of ADT-G can
reflect the total androgenic metabolism.
Labrie et al. (2006) analyzing childbearing and
postmenopausal women also suggested the use of
ADT-G as an androgenic biomarker rather than tes-
tosterone.24 Carmina et al. (2002), found that in
women with only acne the best biomarker would be
the levels of ADT-G, even though at the time he used
a less sensitive method (radioimmunoassay).25
Regarding the treatment effect, it was observed that
the use of COC significantly reduced the levels of
ADT-G, proving the antiandrogenic effect of ethiny-
lestradiol plus drospirenone. Thus, ADT-G, besides a
hormonal biomarker, was also useful in the treatment
follow-up, which was compatible with the clinical
improvement of the lesions.
As expected and already revealed by others studies
the free testosterone levels were significantly reduced
by treatment with COC. The mechanism is in part
due to the increase in hepatic synthesis of SHBG (sex
hormone-binding globulin), induced by the estrogen
contained in the COC.26 The total testosterone and
DHEA-S mean levels showed no alterations with the
treatments.
As was expected, the topical use of AA did not pro-
duce any change in hormone levels, since its systemic
absorption is negligible, less than 4%.27 Therefore is
possible to conclude that although this medication
may block the 5 alpha-reductase, as suggested by
Figure 2. Profile chart of subgroups, ADT-G levels before and
after treatments.
Figure 3. Profile graph of subgroups, free testosterone (FT) levels
before and after treatments.
e1361571-4 M. ROCHA ET AL.
Stamatiadis, this action is not sufficient to alter plasma
concentrations.28
Before the treatment, the cross analysis between FT
and ADT-G levels (Fig. 4), revealed a low coefficient
(r D 0.44), proving a weak correlation among the hor-
mone level (plasmatic) and its main metabolite.
Therefore, in cases of adult female acne, without
other clinical manifestations of hyperandrogenism,
free testosterone should not be considered as a bio-
marker of hormonal activity, since this dosage cer-
tainly underestimates the peripheral conversion
performed by several tissues.
Conclusion
The levels ADT-G were more sensitive in detecting
differences between the control and acne groups, thus
more fully analyzing the androgen metabolism, espe-
cially the peripheral system.
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